Compare McKesson Corporation (MCK) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Rockwell Automation — how do they compare? McKesson Corporation trades at $832.45 (market cap $97.35B), while Rockwell Automation trades at $466.2 (market cap $51.04B). The key difference: McKesson Corporation is the larger of the two by market cap, and Rockwell Automation pays the higher dividend (1.2%). Which is the better fit depends on your goals.
| MCK | ROK | |
|---|---|---|
Market Cap | $97.35B | $51.04B |
Sector | Health | Industrials |
52-Week High | $995.69 | $495.08 |
52-Week Low | $659.01 | $328.67 |
Enterprise Value | $101.98B | $54.67B |
Dividend Yield | 0.39% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $828.84, down 1.49% on the day, with a bullish technical outlook supported by moving averages and key support at $826. The company shows strong revenue growth, reaching $359.05B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with 24 buy ratings and a consensus price target of $932.83, indicating 12.5% upside potential.
The outlook for MCK remains favorable due to consistent earnings beats, robust cash flow generation, and leadership in healthcare distribution. Risks include thin profit margins (1.18% net margin) and high liabilities relative to equity. Investors should focus on execution in specialty pharma and oncology services as key growth drivers amid competitive and regulatory pressures.
Rockwell Automation (ROK) trades at $464.82, up 0.64% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 48.92% gross margin and 12.45% net margin, though valuation multiples like a 47.63 P/E appear elevated. Recent news highlights growth in industrial automation and AI infrastructure partnerships, including a contract with Aalo Atomics for nuclear reactor control systems (PRNewsWire, July 16, 2026).
Outlook is mixed: analyst consensus is a Buy with a $471.71 price target, but technical indicators suggest near-term pressure. Risks include margin compression and high debt levels, while opportunities lie in automation demand and new contracts. The stock offers a dividend yield of approximately 0.6% with consistent payouts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
